<div id="readability-page-1"><p>Y Intercept Hong Kong Ltd bought a new position in shares of  Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the second quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 58,398 shares of the biopharmaceutical company's stock, valued at approximately $1,188,000. Y Intercept Hong Kong Ltd owned about 0.09% of Celldex Therapeutics at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Celldex Therapeutics</strong> alerts:</span></p></div><p>A number of other institutional investors have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. acquired a new position in  Celldex Therapeutics during the second quarter worth $861,000.  Nisa Investment Advisors LLC increased its holdings in shares of  Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 881 shares during the last quarter.  AlphaQuest LLC increased its holdings in shares of  Celldex Therapeutics by 7.0% in the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 844 shares during the last quarter.  TD Asset Management Inc increased its holdings in shares of  Celldex Therapeutics by 62.1% in the second quarter. TD Asset Management Inc now owns 127,878 shares of the biopharmaceutical company's stock valued at $2,602,000 after purchasing an additional 49,000 shares during the last quarter.  Finally, Sovran Advisors LLC bought a new stake in shares of  Celldex Therapeutics in the second quarter valued at about $842,000. </p><h2>Analysts Set New Price Targets</h2><p>A number of brokerages have recently issued reports on CLDX. Barclays assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 13th. They issued an &#34;underweight&#34; rating and a $25.00 target price for the company. HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo &amp; Company lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, August 20th. One equities research analyst  has rated the stock with a Strong Buy rating, seven have assigned  a Buy rating, one  has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $44.20.</p><p><b>Check Out Our Latest Analysis on CLDX</b></p><h2>Celldex Therapeutics Stock Down 7.4%</h2><p>Shares of CLDX opened at $24.75 on Tuesday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $29.05. The business's fifty day moving average is $25.32 and its 200 day moving average is $22.62. The stock has a market cap of $1.64 billion, a P/E ratio of -8.22 and a beta of 1.33. </p><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. On average, analysts expect that  Celldex Therapeutics, Inc. will post -2.48 EPS for the current year. </p><h2>About Celldex Therapeutics</h2> (Free Report)<p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Celldex Therapeutics</li><li>What Are Some of the Best Large-Cap Stocks to Buy?</li><li>Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate</li><li>How to Profit From Growth Investing </li><li>The Best Local Butchers for Thanksgiving [2025 Survey]</li><li>Why Are These Companies Considered Blue Chips?</li><li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li></ul><p><strong>Want to see what other hedge funds are holding CLDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CLDX

<p>Y Intercept Hong Kong Ltd acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during Q2, purchasing 58,398 shares valued at approximately $1.19 million. Other institutional investors also adjusted their stakes in the company. Analysts have set various price targets for CLDX, with a consensus rating of "Moderate Buy" and an average target price of $44.20. The stock has seen a decline of 7.4%, opening at $24.75, with a market cap of $1.64 billion and a P/E ratio of -8.22.</p>

Y Intercept Hong Kong Ltd Takes $1.19 Million Position in Celldex Therapeutics, Inc. $CLDX